SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions

AIM: Herein, we compare outcomes in patients treated with lung stereotactic body radiotherapy (SBRT) with and without tissue confirmation. METHODS: We reviewed 196 patients that underwent lung SBRT for presumed (100 patients) or proven non-small-cell lung cancer (96 patients) over a 10-year period a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wegner, Rodney E, Ahmed, Nissar, Hasan, Shaakir, Schumacher, Lana Y, Van Deusen, Matthew, Colonias, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307539/
https://www.ncbi.nlm.nih.gov/pubmed/30643580
http://dx.doi.org/10.2217/lmt-2018-0006
Descripción
Sumario:AIM: Herein, we compare outcomes in patients treated with lung stereotactic body radiotherapy (SBRT) with and without tissue confirmation. METHODS: We reviewed 196 patients that underwent lung SBRT for presumed (100 patients) or proven non-small-cell lung cancer (96 patients) over a 10-year period and compared outcomes. RESULTS: A total of 196 patients with a median age of 76 underwent lung SBRT to a median dose of 48 Gy in four fractions. Median follow up was 17 months. Local control and overall survival at 3 years was 94 and 58% for the entire group. There was no difference in overall survival, local control, regional control or distant control between the cohorts. CONCLUSION: SBRT is a safe and effective treatment for patients with non-small-cell lung cancer that are medically inoperable with comparable results in empirically treated patients.

Ejemplares similares